Engene Holdings Inc. has successfully priced its public offering, with 12,558,823 common shares at $8.50 per share and pre-funded warrants for 2,735,295 shares at $8.4999 per pre-funded warrant. This offering is expected to generate gross proceeds of approximately $130 million for Engene. The company has also granted the underwriters a 30-day option to purchase up to an additional 2,294,117 common shares at the public offering price. The offering is set to close on or about November 14, 2025.
Engene's lead program, detalimogene voraplasmid, is being evaluated in the ongoing multi-cohort Legend Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. This program was developed using Engene’s proprietary dually derivatized oligochitosan® (DDX) platform, enabling the penetration of mucosal tissues and the delivery of a wide range of cargo, including DNA and various forms of RNA. The market has reacted to these announcements by moving the company's shares 1.19% to a price of $8.53. If you want to know more, read the company's complete 8-K report here.
